Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 10Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1Glioma 1

Interventions

Radiosurgery 28Magnetic Resonance Spectroscopy 15Temozolomide 14pembrolizumab 13Bevacizumab 11Nivolumab 10Ipilimumab 8Memantine 7Specimen Handling 6Radiotherapy 6Mental Status and Dementia Tests 6abemaciclib 5Blood Specimen Collection 5Radiation 4trastuzumab deruxtecan 3entrectinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Sodium Chloride 3Saline Solution 3Receptors, Interleukin-8B 3Proton Therapy 3Biopsy 3trametinib 2pertuzumab 2osimertinib 2lenvatinib 2fluciclovine F-18 2contrast agent BR1 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × Ado-Trastuzumab Emtansine × 90 days × Clear all
NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

NCT05323955 2026-03-17

BRIDGET

Duke University

Phase 2 Active not recruiting
48 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡